FDA panel votes against taking drugs for "low-T"

September 18, 2014 9:23 PM

2 0

FDA panel votes against taking drugs for "low-T"

An FDA advisory panel voted 20-1 Wednesday to design limits around the use of testosterone-replacement therapies, and that more information is needed to assess whether these treatments pose a cardiovascular risk.

While FDA is not required to follow its advisors' advice, if the agency does adhere to the near-unanimous recommendations to rein in the drugs' prescribing, often for a lifestyle-related condition known as “low-T,” could translate into a sales dip for AbbVie's AndroGel and Eli Lilly's Axiron.

Read more

To category page